Chantix

Total: $103.1 million

Pfizer ($PFE) has steadily increased advertising for Pfizer's stop-smoking drug Chantix for several years. In 2014, it spent just over $100 million, up about 30% over the previous year. TV ads center on real people who quit smoking using Chantix, which is marketed as Champix outside the U.S.

Revenue for Chantix was $647 million in 2014, flat from 2013.

Chantix was a hoped-for blockbuster that was stymied by reports of negative side effects. Pfizer, in fact, has gone back and forth with the FDA over safety issues, most recently over Chantix' black box label listing possible psychiatric side effects--one that Pfizer wanted to remove. The FDA recently said the label stays, and should add new warnings about use with alcohol.

For more:
FDA keeps black box on Pfizer's Chantix, adds new warning about alcohol
FDA reviewers say Pfizer's Chantix should keep its black box
Chantix litigation may be wrapped, but safety debate wears on
Pfizer preps its case for FDA pulling Chantix's black-box warning

Chantix
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.